Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Feb;25(2):395–400. doi: 10.1128/jcm.25.2.395-400.1987

Significance of quantitative enzyme-linked immunosorbent assay (ELISA) results in evaluation of three ELISAs and Western blot tests for detection of antibodies to human immunodeficiency virus in a high-risk population.

P Nishanian, J M Taylor, E Korns, R Detels, A Saah, J L Fahey
PMCID: PMC265907  PMID: 3546369

Abstract

The characteristics of primary (first) tests with three enzyme-linked immunosorbent assay (ELISA) kits for human immunodeficiency virus (HIV) antibody were determined. The three ELISAs were performed on 3,229, 3,130, and 685 specimens from high-risk individuals using the Litton (LT; Litton Bionetics Laboratory Products, Charleston, S.C.), Dupont (DP; E. I. du Pont de Nemours & Co., Inc., Wilmington, Del.), and Genetic Systems (GS; Genetic Systems, Seattle, Wash.) kits, respectively. Evaluation was based on the distribution of quantitative test results (such as optical densities), a comparison with Western blot (WB) results, reproducibility of the tests, and identification of seroconverters. The performances of the GS and the DP kits were good by all four criteria and exceeded that of the LT kit. Primary ELISA-negative results were not always confirmed with repeat ELISA and by WB testing. The largest percentage of these unconfirmed negative test results came from samples with quantitative results in the fifth percentile nearest the cutoff. Thus, supplementary testing was indicated for samples with test results in this borderline negative range. Similarly, borderline positive primary ELISA results that were quantitatively nearest (fifth percentile) the cutoff value were more likely to be antibody negative on supplementary testing than samples with high antibody values. In this study, results of repeated tests by GS ELISA showed the least change from first test results. DP ELISA showed more unconfirmed primary positive test results, and LT ELISA showed more unconfirmed primary negative test results. Designation of a specimen with a single ELISA quantitative level near the cutoff value as positive or negative should be viewed with skepticism. A higher than normal proportion of specimens with high negative optical densities by GS ELISA (fifth percentile nearest the cutoff) and also negative by WB were found to be from individuals in the process of seroconversion.

Full text

PDF
395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  2. Carlson J. R., Hinrichs S. H., Levy N. B., Gardner M. B., Holland P., Pedersen N. C. Evaluation of commercial AIDS screening test kits. Lancet. 1985 Jun 15;1(8442):1388–1388. doi: 10.1016/s0140-6736(85)91809-4. [DOI] [PubMed] [Google Scholar]
  3. Courouce A. M. Evaluation of eight ELISA kits for the detection of anti-LAV/HTLV-III antibodies. Lancet. 1986 May 17;1(8490):1152–1153. doi: 10.1016/s0140-6736(86)91863-5. [DOI] [PubMed] [Google Scholar]
  4. Fang C. T., Darr F., Kleinman S., Wehling R. H., Dodd R. Y. Relative specificity of enzyme-linked immunosorbent assays for antibodies to human T-cell lymphotrophic virus, type III, and their relationship to Western blotting. Transfusion. 1986 Mar-Apr;26(2):208–209. doi: 10.1046/j.1537-2995.1986.26286152918.x. [DOI] [PubMed] [Google Scholar]
  5. Field D., Whyte G., Robertson S. Assessment of HTLV III screening tests in Christchurch. N Z Med J. 1985 Nov 27;98(791):992–993. [PubMed] [Google Scholar]
  6. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  7. Holland P. V., Richards C. A., Teghtmeyer J. R., Douville C. M., Carlson J. R., Hinrichs S. H., Pedersen N. C. Anti-HTLV-III testing of blood donors: reproducibility and confirmability of commercial test kits. Transfusion. 1985 Jul-Aug;25(4):395–397. doi: 10.1046/j.1537-2995.1985.25485273826.x. [DOI] [PubMed] [Google Scholar]
  8. Kuritsky J. N., Rastogi S. C., Faich G. A., Schorr J. B., Menitove J. E., Reilly R. W., Bove J. R. Results of nationwide screening of blood and plasma for antibodies to human T-cell lymphotrophic III virus, type III. Transfusion. 1986 Mar-Apr;26(2):205–207. doi: 10.1046/j.1537-2995.1986.26286152917.x. [DOI] [PubMed] [Google Scholar]
  9. Kühnl P., Seidl S., Holzberger G. HLA DR4 antibodies cause positive HTLV-III antibody ELISA results. Lancet. 1985 May 25;1(8439):1222–1223. doi: 10.1016/s0140-6736(85)92910-1. [DOI] [PubMed] [Google Scholar]
  10. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  11. McDougal J. S., Cort S. P., Kennedy M. S., Cabridilla C. D., Feorino P. M., Francis D. P., Hicks D., Kalyanaraman V. S., Martin L. S. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods. 1985 Jan 21;76(1):171–183. doi: 10.1016/0022-1759(85)90489-2. [DOI] [PubMed] [Google Scholar]
  12. Mortimer P. P., Parry J. V., Mortimer J. Y. Which anti-HTLV III/LAV assays for screening and confirmatory testing? Lancet. 1985 Oct 19;2(8460):873–877. doi: 10.1016/s0140-6736(85)90136-9. [DOI] [PubMed] [Google Scholar]
  13. Petricciani J. C. Licensed tests for antibody to human T-lymphotropic virus type III. Sensitivity and specificity. Ann Intern Med. 1985 Nov;103(5):726–729. doi: 10.7326/0003-4819-103-5-726. [DOI] [PubMed] [Google Scholar]
  14. Poiesz B. J., Ruscetti F. W., Gazdar A. F., Bunn P. A., Minna J. D., Gallo R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415–7419. doi: 10.1073/pnas.77.12.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  16. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Weiss S. H., Goedert J. J., Sarngadharan M. G., Bodner A. J., Gallo R. C., Blattner W. A. Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA. 1985 Jan 11;253(2):221–225. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES